Skip to main content
main-content

Oncology

25-05-2018 | Prostate cancer | Highlight | Article

Editor's pick

Further data support aBSI as a prognostic marker in mCRPC

Prospective data confirm use of the automated Bone Scan Index as an independent prognostic marker of survival and other clinical outcomes in men with metastatic castration-resistant prostate cancer, researchers report.

Source:

JAMA Oncol 2018; Advance online publication

25-05-2018 | Colorectal cancer | News | Article

Worse prognosis for patients with V600E BRAF-mutated colorectal liver metastases

The presence of the BRAF V600E mutation in colorectal liver metastases is associated with a worse prognosis and increased risk for recurrence, according to findings from an international retrospective cohort study.

Source:

JAMA Surg 2018; Advance online publication

24-05-2018 | Oncology | News | Article

Tremelimumab plus durvalumab active in unresectable mesothelioma

Preliminary results suggest a role for the combination of the CTLA-4 inhibitor tremelimumab and the PD-L1 blocker durvalumab in the treatment of inoperable pleural or peritoneal mesothelioma.

Source:

Lancet Respir Med 2018; Advance online publication

23-05-2018 | Prostate cancer | News | Article

[177Lu]-PSMA-617 shows promise for heavily pretreated mCRPC

Radionuclide treatment with lutetium-177-prostate-specific membrane antigen-617 shows potential for men with metastatic castration-resistant prostate cancer that has progressed after standard therapy, researchers report.

Source:

Lancet Oncol 2018; Advance online publication

22-05-2018 | Oncology | News | Article

Breath test for esophagogastric cancer diagnosis validated

A noninvasive single breath test has potential for the diagnosis of esophagogastric cancer, say researchers.

Source:

JAMA Oncol 2018; Advance online publication

High-Intensity Follow-Up For CRC Recurrence Fails To Improve Patient Survival

Overall survival after stage I–III colorectal cancer treatment is not associated with the frequency of surveillance for recurrent disease Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

Twitter Icon Follow medwireNews

Click here
image credits